Therapy with Interleukin-22 Alleviates Hepatic Injury and Hemostasis Dysregulation in Rat Model of Acute Liver FailureReportar como inadecuado




Therapy with Interleukin-22 Alleviates Hepatic Injury and Hemostasis Dysregulation in Rat Model of Acute Liver Failure - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Advances in Hematology - Volume 2014 2014, Article ID 705290, 7 pages -

Research ArticleDepartment of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University, P.O. Box 7607, Makkah 7152, Saudi Arabia

Received 8 January 2014; Accepted 4 March 2014; Published 1 April 2014

Academic Editor: Myriam Labopin

Copyright © 2014 Tariq Helal Ashour. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The therapeutic efficacy of interleukin-22 IL-22 on liver injury and hematological disturbances was studied in rat model of acute liver failure ALF induced by D-galactosamine-lipopolysaccharide D-GalN-LPS. The following parameters were investigated: 1 survival rate, 2 serum levels of liver function enzymes aspartate aminotransferase AST, alanine aminotransferase ALT, and alkaline phosphatase ALP, total bilirubin TBILI, and total albumen ALB, 3 blood clotting tests prothrombin time PT, activated partial thromboplastin time aPTT, and fibrinogen level FIB and white blood cells WBCs, red blood cells RBCs, and platelet counts, 4 hepatic levels of tumor necrosis factor-α TNF-α and cyclooxygenase-2 COX-2, and 5 liver histopathology. After 48 hours of D-GalN-LPS, the rats exhibited 20% mortality, significant increases in AST, ALT, ALP, TBILI, PT, and aPTT, TNF-α, and COX-2 and significant decreases in FIB, WBCs, and RBCs. By contrast, therapy with IL-22 prevented the lethal effect of D-GalN-LPS by 100% and efficiently alleviated all the biochemical and hematological abnormalities that were observed in ALF untreated group. Furthermore, IL-22 treatment decreased the hepatic contents of TNF-α and COX-2. The histopathological findings also supported the hepatoprotective effect of IL-22. Taken together, therapy with IL-22 can represent a promising therapeutic tool against liver injury and its associated hemostasis disturbances.





Autor: Tariq Helal Ashour

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados